Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13130743 | 0.80 | — | — | |
| SCHEMBL24631514 | 0.79 | APLNR (0.40) | — | |
| SCHEMBL19501020 | 0.79 | — | — | |
| SCHEMBL19501021 | 0.79 | — | — | |
| SCHEMBL20317383 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12873347 | 0.77 | PRKCA (0.32) | TSHR | |
| SCHEMBL23695895 | 0.77 | EPHX2 (0.35) | ALDH1A1 | |
| SCHEMBL22861632 | 0.77 | EPHX2 (0.35) | ALDH1A1 | |
| SCHEMBL23696041 | 0.77 | EPHX2 (0.35) | ALDH1A1 | |
| SCHEMBL10060469 | 0.77 | ALDH1A1 (0.30) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239835-A9 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250536-A1 | MODIFICATION OF METALLIC SURFACES WITH PHOSPHONIC ACIDS | BIOLOGICAL DYNAMICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20110065739-A1 | NOVEL ISOXAZOLE DRIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065739-A1 | NOVEL ISOXAZOLE DRIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | TSHR 1840/4885ALDH1A1 3165/4885 |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | TSHR 164/4885ALDH1A1 1111/4885 |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | TSHR 2017/4885ALDH1A1 2465/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | TSHR 4791/4885ALDH1A1 1169/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | TSHR 1060/4885ALDH1A1 638/4885 |
| US-20240239835-A9 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | MC2R, NR3C2, AVPR1B | TSHR 224/4885ALDH1A1 1429/4885 |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | TSHR 2254/4885ALDH1A1 4818/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | TSHR 935/4885ALDH1A1 72/4885 |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | TSHR 4744/4885ALDH1A1 1657/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | TSHR 4351/4885ALDH1A1 2571/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | TSHR 3752/4885ALDH1A1 1438/4885 |
| US-20110065739-A1 | NOVEL ISOXAZOLE DRIVATIVE | GPR119, GPR132, GPR180 | TSHR 318/4885ALDH1A1 1403/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | TSHR 2908/4885ALDH1A1 2597/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | TSHR 654/4885ALDH1A1 4573/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | TSHR 146/4885ALDH1A1 302/4885 |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | HBB, IAPP, GLP1R | TSHR 1177/4885ALDH1A1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.